B
HQL

Baird’s abrdn Life Sciences Investors HQL Stock Holding History

Baird’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$341K Buy
12,360
+3,437
+39% +$93.7K ﹤0.01% 1074
2014
Q4 		$222K Sell
8,923
-165
-2% -$3.96K ﹤0.01% 1179
2014
Q3 		$201K Buy
+9,088
New +$197K ﹤0.01% 1049

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Baird's HQL Position: Q1 2015 in Review

Baird increased its abrdn Life Sciences Investors (HQL) stake by 39% in Q1 2015, buying an estimated $93.7K and bringing the position to 12,360 shares worth $341K. The position accounts for ﹤0.01% of the portfolio, ranked #1074.

Baird first reported a position in HQL in Q3 2014 and has held it in 3 quarters since. 45 funds tracked by Wall St. Rank hold HQL as of Q1 2015.

  • Baird held 12,360 shares of abrdn Life Sciences Investors worth $341K as of Q1 2015.
  • Baird bought 3,437 abrdn Life Sciences Investors shares in Q1 2015, an estimated $93.7K.
  • abrdn Life Sciences Investors made up ﹤0.01% of Baird's portfolio in Q1 2015, its #1074 holding.
  • Baird first reported a position in abrdn Life Sciences Investors in Q3 2014 and has held it in 3 quarters since.
  • 45 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.